Lion Biotechnologies, Inc. (IOVA) Issues Quarterly Earnings Results
Lion Biotechnologies, Inc. (NASDAQ:IOVA) posted its quarterly earnings data on Tuesday. The biotechnology company reported ($0.35) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.34) by ($0.01), Bloomberg Earnings reports.
TRADEMARK VIOLATION NOTICE: This article was first posted by Watch List News and is the property of of Watch List News. If you are reading this article on another publication, it was copied illegally and reposted in violation of US and international copyright laws. The original version of this article can be read at https://www.watchlistnews.com/lion-biotechnologies-inc-iova-issues-quarterly-earnings-results/1673697.html.
Several analysts have commented on the company. Oppenheimer Holdings, Inc. set a $13.00 price objective on Lion Biotechnologies and gave the company a “buy” rating in a research note on Tuesday. Chardan Capital reaffirmed a “buy” rating on shares of Lion Biotechnologies in a research note on Thursday, September 7th. B. Riley FBR, Inc. upped their price objective on Lion Biotechnologies from $17.50 to $18.00 and gave the company a “buy” rating in a research note on Wednesday. HC Wainwright reaffirmed a “buy” rating and set a $16.00 price objective on shares of Lion Biotechnologies in a research note on Wednesday, August 16th. Finally, FBR & Co reaffirmed a “buy” rating and set a $17.50 price objective on shares of Lion Biotechnologies in a research note on Wednesday, October 25th. Eleven research analysts have rated the stock with a buy rating, The stock currently has a consensus rating of “Buy” and a consensus price target of $14.53.
About Lion Biotechnologies
Iovance Biotherapeutics, Inc, formerly Lion Biotechnologies, Inc, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products designed to harness the power of a patient’s own immune system to eradicate cancer cells. The Company’s lead program is an adoptive cell therapy utilizing tumor-infiltrating lymphocytes, which are T cells derived from patients’ tumors, for the treatment of metastatic melanoma.
Receive News & Ratings for Lion Biotechnologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lion Biotechnologies Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.